
Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Need Help?
Announcements
8 April 2024
Meet Us at the 2024 ASCO Annual Meeting, 31 May–4 June 2024, Chicago, IL, USA

The 2024 ASCO Annual Meeting will take you to discover state-of-the-art research, groundbreaking treatments, and visionary insights, igniting your passion for oncology. This year's program will feature over 200 sessions, complementing Dr. Lynn Schuchter’s Presidential theme “The Art and Science of Cancer Care: From Comfort to Cure”.
The following MDPI journals will be represented:
- Cancers;
- JPM;
- Pharmaceutics;
- Healthcare;
- JCM;
- CIMB;
- Medical Sciences;
- Clinics and Practice;
- Onco;
- Current Oncology;
- Dermato;
- Pharmacy;
- Biomedicines;
- Diseases;
- Immuno;
- Biologics;
- Vaccines;
- Diagnostics;
- Hemato;
- Venereology.
If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at the booth at the conference and answering any questions you may have. For more information regarding the conference, please visit the following link: https://conferences.asco.org/am/attend.
7 April 2024
Current Oncology | National Oral, Head, and Neck Cancer Awareness Month

National Oral, Head, and Neck Cancer Awareness Month in April is a dedicated period to raise awareness about the risks, prevention, and early detection of oral, head, and neck cancers. Throughout this month, various educational campaigns, screenings, and initiatives are organized to promote understanding, encourage regular check-ups, and emphasize the importance of timely intervention in combating these potentially life-threatening diseases. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of oral, head, and neck cancer, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field. The list of relevant papers can be seen below:
“A Qualitative Study of Patient and Healthcare Provider Perspectives on Building Multiphasic Exercise Prehabilitation into the Surgical Care Pathway for Head and Neck Cancer”
by Julia T. Daun, Rosie Twomey, Joseph C. Dort, Lauren C. Capozzi, Trafford Crump, George J. Francis, T. Wayne Matthews, Shamir P. Chandarana, Robert D. Hart, Christiaan Schrag et al.
Curr. Oncol. 2022, 29(8), 5942-5954; https://doi.org/10.3390/curroncol29080469
Available online: https://www.mdpi.com/1718-7729/29/8/469
“Interventions for the Prevention of Oral Mucositis in Patients Receiving Cancer Treatment: Evidence from Randomised Controlled Trials”
by Giuseppe Colella, Ciro Emiliano Boschetti, Rita Vitagliano, Chiara Colella, Lebei Jiao, Natalie King-Smith, Chong Li, Yii Nuoh Lau, Zacchaeus Lai, Ali Ibrahim Mohammed et al.
Curr. Oncol. 2023, 30(1), 967-980; https://doi.org/10.3390/curroncol30010074
Available online: https://www.mdpi.com/1718-7729/30/1/74
“Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada”
by Jean Lachaine, Kimberly Guinan, Andrew Aw, Versha Banerji, Isabelle Fleury and Carolyn Owen
Curr. Oncol. 2023, 30(5), 4483-4498; https://doi.org/10.3390/curroncol30050339
Available online: https://www.mdpi.com/1718-7729/30/5/339
“Biopsychosocial Markers of Body Image Concerns in Patients with Head and Neck Cancer: A Prospective Longitudinal Study”
by Justine G. Albert, Christopher Lo, Zeev Rosberger, Saul Frenkiel, Michael Hier, Anthony Zeitouni, Karen Kost, Alex Mlynarek, Martin Black, Christina MacDonald et al.
Curr. Oncol. 2022, 29(7), 4438-4454; https://doi.org/10.3390/curroncol29070353
Available online: https://www.mdpi.com/1718-7729/29/7/353
“Rates of Smoking Cessation at 6 and 12 Months after a Clinical Tobacco Smoking Cessation Intervention in Head and Neck Cancer Patients in Northern Ontario, Canada”
by Stacey A. Santi, Michael S. C. Conlon, Margaret L. Meigs, Stacey M. Davidson, Kyle Mispel-Beyer and Deborah P. Saunders
Curr. Oncol. 2022, 29(3), 1544-1558; https://doi.org/10.3390/curroncol29030130
Available online: https://www.mdpi.com/1718-7729/29/3/130
“Extra-Nodal Lymphomas of the Head and Neck and Oral Cavity: A Retrospective Study”
by Alfonso Sorrentino, Francesco Ferragina, Ida Barca, Antonella Arrotta and Maria Giulia Cristofaro
Curr. Oncol. 2022, 29(10), 7189-7197; https://doi.org/10.3390/curroncol29100566
Available online: https://www.mdpi.com/1718-7729/29/10/566
“Clinicopathological Risk Factors for Contralateral Lymph Node Metastases in Intraoral Squamous Cell Carcinoma: A Study of 331 Cases”
by Christian Flörke, Aydin Gülses, Christina-Randi Altmann, Jörg Wiltfang, Henning Wieker and Hendrik Naujokat
Curr. Oncol. 2021, 28(3), 1886-1898; https://doi.org/10.3390/curroncol28030175
Available online: https://www.mdpi.com/1718-7729/28/3/175
“Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration”
by Arslan Babar, Neil M. Woody, Ahmed I. Ghanem, Jillian Tsai, Neal E. Dunlap, Matthew Schymick, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku et al.
Curr. Oncol. 2021, 28(4), 2409-2419; https://doi.org/10.3390/curroncol28040221
Available online: https://www.mdpi.com/1718-7729/28/4/221
Relevant Special Issues:
“Advances in Squamous Cell Carcinoma of the Head and Neck”
Guest Editor: Dr. Dimitra P. Vageli
Available online: https://www.mdpi.com/journal/curroncol/special_issues/advances_hnscc
“New Frontiers in Head and Neck Oncology”
Guest Editors: Dr. George Shenouda, Prof. Dr. Denis Soulieres and Dr. Houda Bahig
Available online: https://www.mdpi.com/journal/curroncol/special_issues/New_Frontiers_Head_Neck_Oncology
“Psychosocial Effects of Head and Neck Cancer”
Guest Editor: Dr. Melissa Henry
Available online: https://www.mdpi.com/journal/curroncol/special_issues/mr_pshychosocial_effects_head_and_neck_cancer
You are welcome to submit relevant papers to the journal Current Oncology. If you have any questions, feel free to contact us.
Current Oncology Editorial Office
2 April 2024
Join Us for the 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), 10–13 June 2024, Rotterdam, the Netherlands

The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) is a four-day congress engaged in basic, preclinical and translational cancer research across a myriad of topics that is aiming to spotlight, inspire and unite the cancer research community to innovate, build knowledge, and create collaborations.
The following MDPI journals will be represented:
- Cancers;
- Cells;
- IJMS;
- Healthcare;
- JCM;
- CIMB;
- Medical Sciences;
- Clinics and Practice;
- Onco;
- JMP;
- Current Oncology.
If you are attending this conference, please feel free to contact us online. Our delegates look forward to meeting you in person and answering any questions you may have. For more information about the conference, please visit the following link: https://2024.eacr.org/.
2 April 2024
MDPI Insights: The CEO's Letter #10 - South Korea, IWD, U2A, Japan

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Left to right: Dr. Jisuk Kang (Scientific Officer, MDPI), Stefan Tochev (CEO, MDPI), and Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), during media meetings at Prain Agency office in Seoul, South Korea.
Visit to Seoul, South Korea
During my recent visit to South Korea, I had the privilege of meeting various stakeholders, including representatives of government, research institutions, and academia, to understand their needs and communicate MDPI’s commitment to accessible science. Accompanied by my colleagues Dr. Giulia Stefenelli and Dr. Jisuk Kang, I engaged with the Korean scientific community, which is increasingly embracing open access (OA).
As the leading OA publisher in South Korea, MDPI is trusted by local authors and in 2023 enjoyed an approximately 30% share of the OA market. South Korea ranks sixth globally for MDPI in terms of research papers submitted and published.
MDPI and South Korea by Numbers
As at 30 March, over 76,000 MDPI articles have been authored by individuals affiliated with Korean institutions. We have over 1,800 active editorial board members (EBMs) from South Korea, with more than 880 EBMs having an H-index between 26 and 50, including 10 serving as Chief Editors.
“South Korea is the sixth-largest contributor to our total publications”
Over the past five years (2019–2023), nearly 120,000 authors affiliated with South Korean institutes have published with MDPI. Specifically in 2023, we received approximately 25,000 submissions from South Korean authors, publishing close to 13,000 articles, resulting in a rejection rate of 47.4%, which is not far below MDPI’s overall rejection rate of 56.4% in 2023.
Institutional Partnerships with South Korea
I am pleased to share that MDPI has more than 825 institutional partnerships worldwide, with 12 in South Korea, including Kyunghee University, Chung-Ang University, and Inha University, among others.
Left to right: Dr. Jisuk Kang (Scientific Officer, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), and Stefan Tochev (CEO, MDPI) fielding media questions at Prain PR Agency office in Seoul, South Korea.
Over the past three years (2021–2023), we have had some of the most prestigious academic universities ranked among the top 10 Korean institutions publishing with MDPI. Seoul National University had the highest number of publications with MDPI during those three years, publishing nearly 6,000 papers. Universities such as Korea University and Yonsei University also rank among the top 10 Korean institutions publishing with MDPI.
MDPI Hosts Seminar for Academia and Media
As the world’s leading OA publisher, MDPI is actively democratizing science. This is reflected in the seminars we hosted on 21 March to address questions about our editorial processes and ethical standards. The visit garnered media coverage, reflecting our mission to providing high-quality services and fostering open dialogue in the community.
“MDPI is actively democratizing science”
MDPI in the News
Stefan Tochev (CEO, MDPI) leading a seminar on OA and MDPI at Prain PR Agency office in Seoul, South Korea.
Media coverage generated by our visit to Seoul included the following stories:
“Open access is an unstoppable trend…it will lead the development of the knowledge ecosystem.”
I greatly appreciate the contributions of everyone who took the time to meet with us, share their stories, and hold us accountable for continuing to provide high-quality publishing services while identifying areas for improvement. I am also excited to announce that we have opened an MDPI office in Seoul and will release a press release on MDPI.com, with details, by the end April 2024. The purpose of the office is to establish a local presence to connect with and support the South Korean academic community through institutional partnerships, conferences, author workshops, stakeholder communications, and more.
Impactful Research
Featured Articles on Women’s Leadership and Healthcare
In celebration of International Women’s Day (8 March 2024), MDPI curated a collection of research articles on various topics, including women’s leadership, reproductive health, preventive healthcare, and a selection of articles from our journal Women.
Women’s Leadership
- Women Entrepreneurship and Sustainable Development: Bibliometric Analysis and Emerging Research Trends
Sustainability 2022, 14, 9160. https://doi.org/10.3390/su14159160 - Refugee Women Business Mentors: New Evidence for Women’s Empowerment
Sustainability 2022, 14, 9154. https://doi.org/10.3390/su14159154 - Women and Leadership in Higher Education: A Systematic Review
Soc. Sci. 2023, 12, 555. https://doi.org/10.3390/socsci12100555 - Understanding Needs and Potentials for Gender-Balanced Empowerment and Leadership in Climate Change Adaptation and Mitigation in Africa
Sustainability 2022, 14, 9410. https://doi.org/10.3390/su14159410 - Challenges Women Experience in Leadership Careers: An Integrative Review
Merits 2023, 3, 366-389. https://doi.org/10.3390/merits3020021
Women’s Reproductive Health
- Recreational Female Athletes’ Understanding of and Perceived Impact of the Menstrual Cycle on Physical Performance, Mood, and Sleeping Behaviour
Women 2023, 3, 445-456. https://doi.org/10.3390/women3030034 - Difficulties in Adaptation of the Mother and Newborn via Cesarean Section versus Natural Birth—A Narrative Review
Life 2023, 13, 300. https://doi.org/10.3390/life13020300 - The Main Theories on the Pathogenesis of Endometriosis
Int. J. Mol. Sci. 2023, 24, 4254. https://doi.org/10.3390/ijms24054254
Women’s Preventive Healthcare
- Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
Int. J. Mol. Sci. 2023, 24, 3140. https://doi.org/10.3390/ijms24043140 - Assessing Barriers Encountered by Women in Cervical Cancer Screening and Follow-Up Care in Urban Bolivia, Cochabamba
Healthcare 2022, 10, 1604. https://doi.org/10.3390/healthcare10091604 - Updates on HPV Vaccination
Diagnostics 2023, 13, 243. https://doi.org/10.3390/diagnostics13020243
Featured Articles in MDPI Journal Women
Below are a few articles from Women, our journal focused on women’s health, the social determinants of health, and the healthcare system that serves women. The aim of Women is to encourage academics to publish their experimental and theoretical results in detail, to aid reproducibility, and in an engaging style, to aid comprehensibility.
- Premenstrual Syndrome and Exercise: A Narrative Review
Women 2023, 3, 348-364. https://doi.org/10.3390/women3020026 - Increasing Awareness of the Human Papillomavirus (HPV) Vaccine for Women 18–45 Years of Age
Women 2023, 3, 365-373. https://doi.org/10.3390/women3030027 - Addressing Women’s Needs with Human Immunodeficiency Virus (HIV) and Enhancing the Visibility of Pharmacists in the Public Health Arena
Women 2022, 2, 346-352. https://doi.org/10.3390/women2040032
Inside MDPI
Championing Women’s Healthcare and Access to Healthcare Information
MDPI colleagues from our offices joined in celebrating #IWD2024. In doing so, we emphasized key missions that encompass:
- Empowering women to assume leadership and decision-making roles in both business and science.
- Helping women and girls make informed decisions about their health.
- Recruiting and developing female talent and fostering inclusive workplace environments.
“We are thrilled to recognize the accomplishments of women scientists”
I am proud to see our colleagues enthusiastically supporting the International Women’s Day call to ‘Inspire Inclusion!’ The heart-hands in the collage below symbolize our appreciation of the achievements of women researchers and the recognition of the trailblazers who have courageously made a mark on societies past and present.
We are thrilled to recognize the accomplishments of women scientists through our many MDPI awards and by highlighting success stories. As inspirational figures, female scientists are paving the way for the next generation of women aspiring to pursue careers in engineering, life sciences, computing, and various other STEM fields.
“I consider myself lucky because I work with incredibly talented women who inspire me every day.”
– Dr. Alessandra Pasut, Winner of MDPI's ‘Biology 2023 Young Investigator Award’
“It’s really important to find a supportive and enabling environment in which to do your science; it would have a big impact on you as a person and on your scientific outputs.”
– Dr. Rhea Longley, Winner of the ‘Pathogens 2023 Young Investigator Award’
Open-access publishing, in particular, allows early-career women researchers to share their work more widely, potentially attracting mentorship opportunities and collaborations. This support is crucial for career development and advancement.
Coming Together for Science
MDPI Joins United2Act in Collective Fight to Stop Paper Mills
In my February 2024 CEO Letter, I highlighted some of our recent initiatives aimed at bolstering our commitment to research integrity, including joining the STM Integrity Hub and expanding our Research Integrity and Publication Ethics team (RIPE). Continuing our efforts in coming together for science, I am pleased to share our participation in the United2Act initiative.
The text below is taken from our official announcement:
United2Act represents an international group of stakeholders in the publishing industry committed to addressing the collective challenge posed to research integrity by paper mills.
Scientists and academic publishers have increasingly noted the alarming proliferation of paper mills, recognized as fraudulent entities seeking to manipulate the publication process for financial profit. These entities engage in fraudulent practices such as falsifying or fabricating data, selling co-authorship of fake papers, manipulating peer review, and including inappropriate citations. These actions pose a significant threat to the integrity of the scholarly record, prompting widespread concern among those involved in the academic community.
MDPI has been actively contributing to combat the undermining of the scientific record. Our editors employ a set of tools to detect potential ethical breaches within a manuscript and to tackle the issue of fake papers.
United2Act’s consensus statement is the outcome of a virtual summit held in May 2023. It involved the participation of research bodies, publishers, researchers/sleuths, universities, and publishing infrastructure from 15 countries and resulted in a Consensus Statement outlining five key areas of action for all stakeholders:
- Education and awareness
- Improve post-publication corrections
- Facilitate and organise research on paper mills
- Enable the development of trust markers
- Facilitate dialogue between stakeholders
MDPI is committed to promoting transparency and integrity in scholarly publishing and is continuing to work closely with the scientific community toward this goal.
Closing Thoughts
Left to right: Ryo Hirayama (Marketing Specialist, MDPI), Takashi Sasabe (Marketing Specialist, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), Dr. Izumi Yamamoto (Marketing Manager, MDPI), and Stefan Tochev (CEO, MDPI), at MDPI’s office in Tokyo, Japan.
Visit to Tokyo and Kyoto, Japan
In March, I had the opportunity to visit our Tokyo office and engage with stakeholders in Tokyo and Kyoto. During the visit, I also recorded a video message to welcome Japanese scholars working with MDPI and to highlight our operations in Japan.
We held meetings with Editors-in-Chief, librarians, scholars, and external consultants to gather feedback on our efforts to enhance our reputation and explore additional steps we can take in that direction. Japan's rich cultural heritage, characterized by tradition, respect, and formality, provided valuable insights into meeting the publishing needs specific to Japan.
Japan’s Open Access statistics
Over the years, we have seen a shift from subscription-only to gold OA publishing in Japan, despite the lack of an official mandate. Here are some statistics:
- 2012: 68% of articles were subscription-only, 6% were green Open Access, and 8% were gold Open Access.
- 2016: 55% of articles were subscription-only, 6% were green Open Access, and 20% were gold Open Access.
- 2022: 43% of articles were subscription-only, 7% were green Open Access, and 39% were gold Open Access.
To learn more about the history of OA in Japan as well as about future trends, please read this blog post.
“Japan is the ninth-largest contributor to our total publications”
Left to right: Stefan Tochev (CEO, MDPI), Dr. Izumi Yamamoto (Marketing Manager, MDPI), and Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI) visiting Kyoto University in Kyoto, Japan.
MDPI and Japan by Numbers
As at 1 April, over 50,000 MDPI articles have been authored by scholars affiliated with Japanese institutions, making the country the ninth-largest contributor to our total publications. Over the past three years (2020–2023), nearly 90,000 authors affiliated with Japanese institutes have published with MDPI, and we have collaborated with over 4,600 Guest Editors from Japan.
In 2023, we published over 8,200 papers from authors associated with Japanese institutions. MDPI collaborates with 41 institutional partnerships in Japan, including the University of Tokyo, Hokkaido University, and Nagoya University. We have over 2,100 active EBMs from Japan, more than 1,050 EBMs having an H-index between 26 and 50, including 13 serving as Editors-in-Chief.
General Feedback – a side note
A general takeaway from our discussions with stakeholders from around the world is that negative perceptions of MDPI often stem from misinformation, misconceptions, or misunderstandings about MDPI and our practices. While we acknowledge our mistakes and work diligently to address them, maintaining a strong editorial procedure and robust peer-review process, I find that educating stakeholders about our how we do what we do and our ongoing improvements tends to help shift opinions.
That said, we recognize the importance of addressing individual concerns. We take feedback seriously and are continuously working to get better while not compromising the core principles that millions of authors appreciate about MDPI.
Chief Executive Officer
MDPI AG
27 March 2024
Prof. Dr. Matthias May Appointed Section Editor-in-Chief of Section “Genitourinary Oncology” in Current Oncology
We are pleased to announce that Prof. Dr. Matthias May has been appointed Section Editor-in-Chief of the Section “Genitourinary Oncology” in Current Oncology (ISSN: 1718-7729). Prof. Dr. Matthias May, born in Berlin (Germany), is a Professor of Urology at St. Elisabeth Hospital Straubing (Bavaria, Germany). Additionally, he holds a teaching position at the Department of Urology, University of Regensburg (Bavaria, Germany). His primary professional focus is operative urologic oncology surgery, including robot-assisted procedures. He maintains a broad scientific interest in urology, particularly in developing prognostic prediction models (including biomarker-based) for various urologic cancers across diverse clinical settings. In recent years, his research has increasingly focused on translational projects involving penile, prostate, and bladder cancer. Prof. Dr. May has secured multiple grants for his research endeavors and has initiated/founded more than 30 multicenter studies. He has authored over 250 peer-reviewed articles, serving as the first or senior author for most of them. Presently, his h-index stands at 39, with 5,802 citations to his work (i10-index: 137).
The following is a short Q&A with Prof. Dr. Matthias May, who has shared his vision for the journal's advancement and impact, the promising future of genitourinary oncology research, and his positive view on the development of open access in the publishing field:
1. What appealed to you about the journal that made you want to take the role of its Section Editor-in-Chief?
Current Oncology has always stood out to me as a beacon of excellence and innovation in the landscape of medical research publishing. Its long-standing tradition of fostering rigorous scientific inquiry and disseminating cutting-edge findings in oncology resonated deeply with my professional ethos and aspirations. Serving as the Section Editor-in-Chief for “Genitourinary Oncology” is not just an honor; it represents a unique opportunity to contribute to the advancement of a field that is at the cusp of transformative breakthroughs. I was particularly drawn to the journal's commitment to integrity, inclusivity, and the promotion of multidisciplinary collaboration, which aligns perfectly with my vision of pushing the boundaries of genitourinary oncology research.
2. What is your vision for the journal?
My vision for Current Oncology is its elevation to unprecedented levels of influence and innovation in the field of genitourinary oncology. In my role, I aim to champion the integration of multidisciplinary research approaches, bridging the gap between basic science, clinical research, and patient care. By doing so, we can provide a holistic perspective on the complexities of cancer diagnosis and treatment, fostering innovations that are both scientifically profound and clinically applicable. Furthermore, I am committed to enhancing the journal's accessibility and global reach, ensuring that cutting-edge research is available to a wide audience, thereby accelerating the translation of research discoveries into clinical practice.
3. What does the future of this field of genitourinary oncology look like?
The future of genitourinary (GU) oncology is incredibly promising, marked by rapid advancements in precision and interventional medicine, as well as personalized treatment plans. We are on the cusp of a paradigm shift where molecular genetics and biomarker research will significantly enhance our understanding of GU cancers and improve their treatment. Furthermore, the integration of artificial intelligence and machine learning in diagnostics and treatment planning holds tremendous potential to revolutionize patient care. As these technologies evolve, we will see a more tailored approach to oncology, prioritizing the patient’s and tumor’s unique genetic profile, patient lifestyle, and quality of life, as well as treatment preferences. In the coming years, I anticipate a more collaborative and interdisciplinary approach to research, driving innovations that will substantially improve outcomes for patients with GU cancers.
4. What do you think of the development of open access in the publishing field?
The development of open access in the publishing field is a transformative movement that democratizes knowledge and accelerates scientific discovery. By making research findings freely available, open access enhances the visibility and impact of scholarly work, facilitating greater collaboration and innovation across disciplines. This model encourages a more inclusive scholarly community, where valuable insights are not hidden behind paywalls, but shared widely, contributing to the collective advancement of science. While there are challenges to navigate, particularly regarding sustainable funding models and ensuring the quality of published work, the benefits of open access in fostering a more informed and engaged global research community are undeniable. As Section Editor-in-Chief, I am committed to supporting and advancing open access initiatives, recognizing their critical role in the future of academic publishing.
We wish Prof. Dr. Matthias May every success in his position as Section Editor-in-Chief, and we look forward to his future contributions to the journal.
26 March 2024
Current Oncology | Kidney Cancer Awareness Month
Kidney cancer, also known as renal cell carcinoma, is a type of cancer that forms in the kidneys. It typically originates in the cells lining the small tubes within the organ. Treatment options include surgery, targeted therapy, and immunotherapy. March is the Kidney Cancer Awareness Month. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the field of kidney cancer, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field. The list of relevant papers is presented below.
“Prospective Evaluation of Kidney Function in Long-Term Survivors of Pediatric CNS Tumors”
by Natalia Stepien, Viktoria Handler, Johannes Gojo, Amedeo A. Azizi, Lisa Mayr, Chryssa Grylli, Daniela Schwarz, Monika Chocholous, Irene Slavc, Michael Boehm et al.
Curr. Oncol. 2022, 29(8), 5306–5315; https://doi.org/10.3390/curroncol29080421
Available online: https://www.mdpi.com/1718-7729/29/8/421
“Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma”
by Luisa M. Cardenas, Jasna E. Deluce, Shahrukh Khan, Omar Gulam, Saman Maleki Vareki, Ricardo Fernandes and Aly-Khan A. Lalani
Curr. Oncol. 2022, 29(8), 5426–5441; https://doi.org/10.3390/curroncol29080429
Available online: https://www.mdpi.com/1718-7729/29/8/429
“Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature”
by Alexius John, Lavinia Spain and Anis A. Hamid
Curr. Oncol. 2023, 30(1), 923–937; https://doi.org/10.3390/curroncol30010070
Available online: https://www.mdpi.com/1718-7729/30/1/70
“Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists”
by Irena Druce, Karine Tawagi, Julie L. V. Shaw, Andrea Ibrahim, Heather Lochnan and Michael Ong
Curr. Oncol. 2022, 29(7), 4665–4677; https://doi.org/10.3390/curroncol29070370
Available online: https://www.mdpi.com/1718-7729/29/7/370
“Virtual Resection: A New Tool for Preparing for Nephron-Sparing Surgery in Wilms Tumor Patients”
by Jasper M. van der Zee, Matthijs Fitski, Frank F. J. Simonis, Cornelis P. van de Ven, Aart J. Klijn, Marc H. W. A. Wijnen and Alida F. W. van der Steeg
Curr. Oncol. 2022, 29(2), 777–784; https://doi.org/10.3390/curroncol29020066
Available online: https://www.mdpi.com/1718-7729/29/2/66
“Trop-2 in Upper Tract Urothelial Carcinoma”
by Eisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, Ken Kuwahara, Takafumi Minami, Taigo Kato, Koji Hatano, Atsunari Kawashima, Motohide Uemura, Tetsuya Takao et al.
Curr. Oncol. 2022, 29(6), 3911–3921; https://doi.org/10.3390/curroncol29060312
Available online: https://www.mdpi.com/1718-7729/29/6/312
“Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art”
by Gianluigi Califano, Idir Ouzaid, Paul Laine-Caroff, Arthur Peyrottes, Claudia Collà Ruvolo, Benjamin Pradère, Vincent Elalouf, Vincent Misrai, Jean-François Hermieu, Shahrokh F. Shariat et al.
Curr. Oncol. 2022, 29(2), 687–697; https://doi.org/10.3390/curroncol29020060
Available online: https://www.mdpi.com/1718-7729/29/2/60
“Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies”
by Ioannis A. Voutsadakis
Curr. Oncol. 2022, 29(3), 1390–1407; https://doi.org/10.3390/curroncol29030117
Available online: https://www.mdpi.com/1718-7729/29/3/117
Relevant Special Issue:
“Current Advances in Clinical Genomics and Treatment of Urothelial Carcinoma”
Guest Editor: Dr. Panagiotis J. Vlachostergios
You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.
Current Oncology Editorial Office
12 March 2024
Current Oncology | National Colorectal Cancer Awareness Month
Colorectal cancer is the third most common cancer worldwide, originating in the colon or rectum and characterized by uncontrolled cell growth in their lining. Early detection through screenings is vital for successful treatment and improved survival rates. March is the National Colorectal Cancer Awareness Month. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in the field of colorectal cancer, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field. The list of relevant papers is presented below.
“Colorectal Cancer and Onset of Anxiety and Depression: A Systematic Review and Meta-Analysis”
by Vicki Cheng, Niki Oveisi, Helen McTaggart-Cowan, Jonathan M. Loree, Rachel A. Murphy and Mary A. De Vera
Curr. Oncol. 2022, 29(11), 8751–8766; https://doi.org/10.3390/curroncol29110689
Available online: https://www.mdpi.com/1718-7729/29/11/689
“Tumor Stroma Ratio and Its Significance in Locally Advanced Colorectal Cancer”
by Luz Sullivan, Richard R. Pacheco, Michel Kmeid, Anne Chen and Hwajeong Lee
Curr. Oncol. 2022, 29(5), 3232–3241; https://doi.org/10.3390/curroncol29050263
Available online: https://www.mdpi.com/1718-7729/29/5/263
“COVID-19 Impact on Diagnosis and Staging of Colorectal Cancer: A Single Tertiary Canadian Oncology Center Experience”
by Mathias Castonguay, Rola El Sayed, Corentin Richard, Marie-France Vachon, Rami Nassabein, Danielle Charpentier and Mustapha Tehfé
Curr. Oncol. 2022, 29(5), 3282–3290; https://doi.org/10.3390/curroncol29050268
Available online: https://www.mdpi.com/1718-7729/29/5/268
“Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes”
by Nicolas Voizard, Tiffany Ni, Alex Kiss, Robyn Pugash, Michael Jonathon Raphael, Natalie Coburn and Elizabeth David
Curr. Oncol. 2022, 29(1), 209–220; https://doi.org/10.3390/curroncol29010020
Available online: https://www.mdpi.com/1718-7729/29/1/20
“Predictive Factors for Anastomotic Leakage Following Colorectal Cancer Surgery: Where Are We and Where Are We Going?”
by Christos Tsalikidis, Athanasia Mitsala, Vasileios I. Mentonis, Konstantinos Romanidis, George Pappas-Gogos, Alexandra K. Tsaroucha and Michail Pitiakoudis
Curr. Oncol. 2023, 30(3), 3111–3137; https://doi.org/10.3390/curroncol30030236
Available online: https://www.mdpi.com/1718-7729/30/3/236
“Persisting Deficits in Health-Related Quality of Life of Colorectal Cancer Survivors 14–24 Years Post-Diagnosis: A Population-Based Study”
by Melissa S. Y. Thong, Daniela Doege, Linda Weißer, Lena Koch-Gallenkamp, Lina Jansen, Heike Bertram, Andrea Eberle, Bernd Holleczek, Alice Nennecke, Annika Waldmann et al.
Curr. Oncol. 2023, 30(3), 3373–3390; https://doi.org/10.3390/curroncol30030257
Available online: https://www.mdpi.com/1718-7729/30/3/257
“Clinical Delays and Comparative Outcomes in Younger and Older Adults with Colorectal Cancer: A Systematic Review”
by Matthew Castelo, Colin Sue-Chue-Lam, Lawrence Paszat, Adena S. Scheer, Bettina E. Hansen, Teruko Kishibe and Nancy N. Baxter
Curr. Oncol. 2022, 29(11), 8609–8625; https://doi.org/10.3390/curroncol29110679
Available online: https://www.mdpi.com/1718-7729/29/11/679
“Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More”
by Balázs Pécsi and László Mangel
Curr. Oncol. 2023, 30(1), 908–922; https://doi.org/10.3390/curroncol30010069
Available online: https://www.mdpi.com/1718-7729/30/1/69
You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.
Current Oncology Editorial Office
4 March 2024
MDPI Insights: The CEO's Letter #9 - Romania, Research Integrity, Viruses

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Reka Kovacs (Deputy Office Manager, MDPI), Stefan Tochev (CEO, MDPI), and Sandra Ana Spatariu (Office Manager, MDPI) at the MDPI office in Cluj, Romania.
MDPI’s Impact on Romania
In February, I visited our office in Cluj, Romania. I worked closely with our senior office managers and various teams, including the departments of training, marketing and conferences, as well as our journal relationship specialists, reviewing our service to the local scholarly community. During the visit, I also met with representatives from Babes-Bolyai University and the Technical University of Cluj-Napoca. Our multifunctional Romanian office plays an important role in supporting our collaborations with the local market as well as helping to meet MDPI’s overall business needs.
Feedback and strategy meeting with a group of MDPI’s Journal Relationship Specialists at the MDPI office in Cluj, Romania.
With 22,436 articles, Romania ranks as a top 20 contributing country to MDPI’s total number of papers published as at 28 February 2024. This highlights the importance of our collaboration with Romanian-affiliated authors and the growing opportunity to support their publishing needs. MDPI is one of the few academic publishers with a significant presence in Romania, boasting over 360 colleagues across our offices in Bucharest and Cluj. We are also proud to hire colleagues from local institutions to launch their careers within publishing.
Romania ranks as a top 20 contributing country.
The Numbers: 2019–2023
MDPI has seen a healthy increase in submissions from Romanian authors over the past three years, from 8,439 in 2021 to 11,866 by end of 2023, with most submissions going to journals such as Sustainability, Medicina, Diagnostics, IJMS, Applied Sciences, and JCM. From 2019 to 2023, MDPI published articles from 32,145 authors affiliated with Romanian institutions. Over those years, we have worked with Romanian Guest Editors on nearly 3,000 occasions to support their Special Issue and Topical collections.
With more than 300 Editorial Board Members from Romania, 34 appear on the board of Mathematics, 27 on Materials, 19 on Polymers, 18 on Coatings, and 16 on Molecules, while three serve as Section Editors-in-Chief (SEiC) on our journals Coatings (3.4 IF, 4.6 Citescore), Magnetochemistry (2.7 IF, 3.5 Citescore), and Chemosensors (4.2 IF, 3.9 Citescore).
Institutional Open Access Programs
Our commitment to working with institutions is evident in Romania, where we have established eight Institutional Open Access Programs (IOAP) with esteemed institutions such as the University of Bucharest, the University of Medicine and Pharmacy Cluj-Napoca, and most recently the National Institute for Laser, Plasma and Radiation Physics.
Our growth and presence in Romania are a true testament.
We also have IOAP agreements with Babes-Bolyai University and the Technical University of Cluj-Napoca, where I had the opportunity to meet senior stakeholders during my visit. Below are a few photos capturing our meeting with Prof. Radu Silaghi-Dumitrescu (Head of Faculty of Chemistry, Babes-Bolyai University) at the MDPI office in Cluj, Romania, along with a photo from our meeting with Vice Deans Nicoleta Cobarzan, Nicoleta Ilies, and Hoda Gavril, from the faculty of Civil Engineering at the Technical University of Cluj, Romania.


Our growth and presence in Romania are a true testament to the service we provide to the scholarly community and the relationships we foster in that region. We look forward to continuing to support Romanian scholars and institutions by providing a valuable and trusted experience with MDPI, the leader in open access publishing.
Impactful Research
MDPI Joins the STM Integrity Hub
MDPI has long been a supporter and partner of STM, with our involvement ranging from sponsoring and attending events to helping organize event programs. By joining the STM Integrity Hub, we aim to further our commitment to STM initiatives aimed at safeguarding the integrity of science.
“We are pleased to welcome MDPI as the 35th organisation participating in the Hub. This expansion is critical, as every new member enhances our capacity to prevent fraudulent submissions from entering the academic record.”
Joris van Rossum, Director of Research Integrity, STM
MDPI operates in full alignment with STM Integrity Hub's values of shared data and experiences. We strongly believe in collaboration and open exchange for the purposes of creating a holistic approach to support research integrity at MDPI itself and across the entire academic publishing industry. The Integrity Hub is an excellent example of how publishers can come together to jointly address industry-wide challenges related to research integrity, such as manuscripts that breach research integrity standards and paper-mills.
I look forward to our Research Integrity and Publication Ethics Team (RIPE) team immersing themselves in this initiative, exchanging information, best practices, and tools for the benefit of the entire scholarly ecosystem. We believe that ethical publishing standards should be implemented across the board, and we aim to be rigorous in our approach, addressing research integrity issues and improving the impact of published research.
Inside MDPI
MDPI Expands Research Integrity and Publication Ethics Team (RIPE)
In addition to external collaborations and joint initiatives aimed at further strengthening our commitment to research integrity, we are also enhancing our internal efforts. This includes improving our processes and guidelines and expanding our teams and departments to ensure quality assurance throughout our publishing process.
We are pleased to announce the expansion of our Research Integrity and Publication Ethics Team (RIPE) at MDPI. The RIPE team has recently welcomed new colleagues, each bringing unique skills and a personal commitment to prioritize ethical considerations in all our work.
The demand for research integrity and high ethical standards in academic publishing is steadily rising across our industry. Our expanded RIPE team will work to enhance and align our practices with industry best practices, ensuring excellence in research integrity and publication ethics.
Stefan Tochev (CEO, MDPI) introduces Dr. Tim Tait-Jamieson (Research Integrity Lead, MDPI) for his presentation on MDPI’s Retraction and Approval Process to a group of Journal Relationship Specialists at the MDPI office in Cluj, Romania: “The demand for research integrity and publication ethics is steadily rising across our industry.”
Introducing our Research Integrity and Publication Ethics Team
Led by Dr. Tim Tait-Jamieson (Research Integrity Lead), the RIPE team comprises Dr. Ivana Resanovic (Research Integrity Manager), Dr. Lavinia Rogojina (Research Integrity Manager), Ms. Diana Apodaritei (Research Integrity Specialist), Dr. Zoltan Mihaly (Research Integrity Specialist), Mr. Aleksandar Đukić (Research Integrity Specialist), Ms. Ana Stankovic (Research Integrity Specialist), and Ms. Anna Pena (Publication Ethics Assistant).
Please click here to access everything that you need to know about MDPI’s Research and Publication Ethics.
With this span of complementary roles, the RIPE team collaborates directly with journal editorial teams and works closely with various departments, including our Scientific Office Board and our Journal Relationship Specialists. The team’s primary objectives are to help prevent issues regarding research integrity and publication ethics during peer review, uphold MDPI’s ethics policies, adhere to industry standards, and resolve publication ethics and research integrity issues and complaints.
Quality Updates to Special Issues Oversight
At MDPI, we are committed to reviewing policies pertaining to the quality of research. In this blog post, Shaheena Patel (Communications Associate, MDPI), outlines two recent updates to MDPI journal processes. These updates pertain to Special Issue (SI) quality guidelines, in line with criteria provided by COPE and DOAJ. Alongside the SI updates, details regarding the new minor corrections policy introduced in 2024 are provided in the blog.
The two updates we implemented include greater oversight and the verification of Guest Editor credentials. These guidelines require that Editors-in-Chief (EiCs) and Editorial Board Members (EBMs) take responsibility for overseeing SIs.
PS. Thank you, James Butcher, for featuring this up in your 67th issue of the Journalogy newsletter.
Read more:
Coming Together for Science
Viruses 2024 – A World of Viruses
I am pleased to share the success of our MDPI conference Viruses 2024 – A World of Viruses, held 14-16 February, in Barcelona. With 240 registrations, this event brought together top scientists, researchers, and industry experts from 40 countries to share their findings on the latest developments in viral pathogenesis and immune responses.
Attendees gathered for the 5th edition of the Viruses’ conference, where we hosted influential keynote speeches from Nobel Prize laureate Dr. Charles M. Rice and ‘Distinguished Senior Virologist’ Prof. Luis Enjuanes, along with 14 invited speakers, 47 selected speakers, and nine flash poster presenters, to discuss the most significant issues in virology today.
Recap on the #Viruses2024 Conference
Take a look at the key moments from MDPI’s Viruses event and please join us in commemorating a gathering for global knowledge and cooperation. A heartfelt thank-you to all attendees; their passion and engagement played a crucial role in making this event an engaging success!
Below are calls to action from the keynote speakers encouraging collaboration and communication:
“There’s never been a better time than now to really take the power that we have both in terms of basic research and also in biotech and pharma to develop antiviral agents.” - Dr. Charles M. Rice, The Rockefeller University, New York, USA
“The collaboration between labs is absolutely essential. Improving initial detection and improving communication is a must for all of us working in science.” - Prof. Dr. Luis Enjuanes, National Center of Biotechnology (CNB-CSIC), Madrid, Spain
Our thanks go to our sponsors and partnering societies, our Viruses journal and editorial team, our Barcelona colleagues, and the social media, conference and other MDPI teams for making this event a memorable occasion. View the event gallery here.
Upcoming In-Person Event
24–26 April, 2024
4th MMCS – Harnessing the Power of New Drug Modalities
Location: Barcelona, Spain
Esteemed speakers at MMCS 2024 include Prof. Arun K. Ghosh, the mind behind the Darunavir molecule, and Prof. Paul Brennan, CSO of Alzheimer's Research UK Oxford Drug Discovery Institute.
Find more upcoming MDPI events here.
Organize Your Event with MDPI’s Sciforum
Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.
Closing Thoughts
Researcher to Reader (R2R) Conference
From 20–21 February 2024, I had the pleasure of attending the Researcher to Reader (R2R) conference in London, which MDPI has proudly sponsored over the years. The conference programme offered a variety of session formats, including workshops, panel discussions, debates, interviews, presentations, and lightning talks, with opportunities to discuss relevant topics.
We take pride in supporting the scientific community, bringing researchers across the world together to network, exchange ideas and share the latest in science and publishing. In 2023, MDPI invested close to 2 million CHF in sponsoring over 2,000 scientific and publishing-related conferences worldwide.
R2R Peer Review Innovations Workshop
I found the R2R conference to be engaging, with the workshops being particularly enjoyable. My colleague Giulia Stefenelli (Chair of Scientific Office Board) and I participated in the “Peer Review Innovations” workshop, which spanned four sessions over the two days. These sessions explored the future of peer review and how we can improve the peer review process for everyone involved. Notably, the large majority of attendees expressed their opinion that peer review, as currently practiced, requires significant improvement. Together, we collaborated on potential immediate and long-term improvements and innovative processes, aiming to create an ecosystem beneficial to all stakeholders by strengthening submission systems with the aim of reducing threats and making authors more responsible for their work. We also discussed the opportunity for academic institutions to better scrutinize the quality of the work produced and submitted to journals.
Our group comprised publishers, software providers, librarians, and more, bringing diverse perspectives to the discussions. These interactions were relevant to MDPI’s ongoing conversations, providing insights to our efforts. The session also made me appreciate that MDPI is doing well, as the group discussions included the subject of various quality checks that we have already embedded in our processes, ensuring that we keep abreast of industry standards.
The need for an optimized system to incentivize the activities of editors and reviewers was also a focus of discussion, as well as the support that reviewers need from publishers via the provision of strong reports through fixed forms, questionnaires and training.
At MDPI, we are currently auditing our reviewer program to improve reviewer recognition, guidelines, and methods for identifying suitable reviewers, while maintaining our commitment to quality and timeliness.
Congratulations to Mark Carden, Conference Director, and the R2R team for organizing a productive and successful event. PS: The break times were greatly appreciated as well!
Chief Executive Officer
MDPI AG
29 February 2024
Current Oncology | Collaboration with The Canadian Centre for Applied Research in Cancer Control (ARCC)

In January 2024, Current Oncology (ISSN: 1718-7729) began to cooperate with the Canadian Centre for Applied Research in Cancer Control (ARCC). As part of this collaboration, all the members of ARCC will enjoy a discount on the Article Processing Charge (APC) when submitting articles to Current Oncology. The collaboration goes beyond the discount offered to members and includes other services, as well as cross promotion.
The Canadian Centre for Applied Research in Cancer Control (ARCC) is an innovative pan-Canadian research center whose mission is to improve cancer control and the delivery of care through interdisciplinary leadership in health economics, services, policy, and ethics research, education and knowledge translation.
We achieve our mission by making improvements across the cancer control spectrum, from prevention, screening and diagnosis to treatment, rehabilitation, survivorship or palliative care. We accomplish this through our dynamic network. The ARCC has provincial representation across Canada.
The ARCC is a professional organization whose functions are highly relevant to the scope of Current Oncology. We look forward to collaborating with the ARCC and publishing state-of-the-art research from its members.
For more information about societies cooperated with Current Oncology, please visit the following link: https://www.mdpi.com/journal/curroncol/societies.
7 February 2024
Current Oncology | International Childhood Cancer Day
International Childhood Cancer Day (15 February) is a global collaborative effort to deepen the understanding of the difficulties faced by children and adolescents with cancer, as well as by survivors and their families, and to raise awareness of these issues. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in the field of childhood cancers, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.
The list of relevant papers can be seen below:
- “Peer Support Needs and Preferences for Digital Peer Navigation among Adolescent and Young Adults with Cancer: A Canadian Cross-Sectional Survey”
by Jacqueline L. Bender, Natasha Puri, Sarah Salih, Norma M. D’Agostino, Argerie Tsimicalis, A. Fuchsia Howard, Sheila N. Garland, Karine Chalifour, Emily K. Drake, Anthony Marrato et al.
Curr. Oncol. 2022, 29(2), 1163–1175; https://doi.org/10.3390/curroncol29020099
Available online: https://www.mdpi.com/1718-7729/29/2/99 - “The Chemo-Gut Pilot Study: Associations between Gut Microbiota, Gastrointestinal Symptoms, and Psychosocial Health Outcomes in a Cross-Sectional Sample of Young Adult Cancer Survivors”
by Julie M. Deleemans, Faye Chleilat, Raylene A. Reimer, Mohamad Baydoun, Katherine-Ann Piedalue, Dana E. Lowry, Jan-Willem Henning and Linda E. Carlson
Curr. Oncol. 2022, 29(5), 2973–2994; https://doi.org/10.3390/curroncol29050243
Available online: https://www.mdpi.com/1718-7729/29/5/243 - “The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review”
by Stephanie J. Kendall, Jodi E. Langley, Mohsen Aghdam, Bruce N. Crooks, Nicholas Giacomantonio, Stefan Heinze-Milne, Will J. Johnston, Melanie R. Keats, Sharon L. Mulvagh and Scott A. Grandy
Curr. Oncol. 2022, 29(9), 6350–6363; https://doi.org/10.3390/curroncol29090500
Available online: https://www.mdpi.com/1718-7729/29/9/500 - “The Transformation of Adolescent and Young Adult Oncological and Supportive Care in Canada: A Mixed Methods Study”
by Jonathan Avery, Emily Wong, Christine Harris, Stacy Chapman, Serena Uppal, Shaayini Shanawaz, Annemarie Edwards, Laura Burnett, Tushar Vora and Abha A. Gupta
Curr. Oncol. 2022, 29(7), 5126–5138; https://doi.org/10.3390/curroncol29070406
Available online: https://www.mdpi.com/1718-7729/29/7/406 - “Recruiting Adolescent and Young Adult Cancer Survivors for Patient-Reported Outcome Research: Experiences and Sample Characteristics of the SURVAYA Study”
by Carla Vlooswijk, Lonneke V. van de Poll-Franse, Silvie H. M. Janssen, Esther Derksen, Milou J. P. Reuvers, Rhodé Bijlsma, Suzanne E. J. Kaal, Jan Martijn Kerst, Jacqueline M. Tromp, Monique E. M. M. Bos et al.
Curr. Oncol. 2022, 29(8), 5407–5425; https://doi.org/10.3390/curroncol29080428
Available online: https://www.mdpi.com/1718-7729/29/8/428 - “Utilization, Delivery, and Outcomes of Dance/Movement Therapy for Pediatric Oncology Patients and their Caregivers: A Retrospective Chart Review”
by Karolina Bryl, Suzi Tortora, Jennifer Whitley, Soo-Dam Kim, Nirupa J. Raghunathan, Jun J. Mao and Susan Chimonas
Curr. Oncol. 2023, 30(7), 6497–6507; https://doi.org/10.3390/curroncol30070477
Available online: https://www.mdpi.com/1718-7729/30/7/477 - “Adherence to Oral Chemotherapy in Acute Lymphoblastic Leukemia during Maintenance Therapy in Children, Adolescents, and Young Adults: A Systematic Review”
by Xiaopei L. Zeng, Mallorie B. Heneghan and Sherif M. Badawy
Curr. Oncol. 2023, 30(1), 720–748; https://doi.org/10.3390/curroncol30010056
Available online: https://www.mdpi.com/1718-7729/30/1/56 - “Setting Priorities for a Provincial Adolescent and Young Adult Oncology Program”
by Julian Surujballi, Grace Chan, Caron Strahlendorf and Amirrtha Srikanthan
Curr. Oncol. 2022, 29(6), 4034–4053; https://doi.org/10.3390/curroncol29060322
Available online: https://www.mdpi.com/1718-7729/29/6/322
You are welcome to submit relevant papers to the journal Current Oncology. If you have any questions, feel free to contact us.
Current Oncology Editorial Office